

SAFETY DATA SHEET



Etoricoxib Formulation



Version Revision Date: SDS Number: Date of last issue: 10/02/2020
3.6 04/09/2021 26531-00019 Date of first issue: 10/29/2014

SECTION 1. IDENTIFICATION

Product name : Etoricoxib Formulation
Other means of identification : No data available

Manufacturer or supplier's details

Company name of supplier : Organon & Co.
Address : 30 Hudson Street, 33rd floor
 Jersey City, New Jersey, U.S.A 07302
Telephone : 551-430-6000
Emergency telephone : 215-631-6999
E-mail address : EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical
Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the Hazardous Products Regulations

Carcinogenicity (Inhalation) : Category 2
Reproductive toxicity : Category 2
Specific target organ toxicity : Category 2 (Kidney, Liver, Gastrointestinal tract)
- repeated exposure (Oral)

GHS label elements

Hazard pictograms :



Signal Word : Warning

Hazard Statements : H351 Suspected of causing cancer if inhaled.
 H361d Suspected of damaging the unborn child.
 H373 May cause damage to organs (Kidney, Liver,
 Gastrointestinal tract) through prolonged or repeated exposure if
 swallowed.

Precautionary Statements : **Prevention:**
 P201 Obtain special instructions before use.
 P202 Do not handle until all safety precautions have been read
 and understood.
 P260 Do not breathe dust.
 P280 Wear protective gloves, protective clothing, eye protection
 and face protection.

Response:

SAFETY DATA SHEET



Etoricoxib Formulation



Version 3.6 Revision Date: 04/09/2021 SDS Number: 26531-00019 Date of last issue: 10/02/2020
Date of first issue: 10/29/2014

P308 + P313 IF exposed or concerned: Get medical attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	Common Name/Synonym	CAS-No.	Concentration (% w/w)
Cellulose	No data available	9004-34-6	$\geq 30 - < 60$ *
Etoricoxib	No data available	202409-33-4	$\geq 10 - < 30$ *
Titanium dioxide	Titanic anhydride	13463-67-7	$\geq 1 - < 5$ *

* Actual concentration or concentration range is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.
- In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : Suspected of causing cancer if inhaled.
Suspected of damaging the unborn child.
May cause damage to organs through prolonged or repeated exposure if swallowed.
Contact with dust can cause mechanical irritation or drying of

SAFETY DATA SHEET



Etoricoxib Formulation



Version 3.6 Revision Date: 04/09/2021 SDS Number: 26531-00019 Date of last issue: 10/02/2020
Date of first issue: 10/29/2014

Protection of first-aiders : the skin.
Dust contact with the eyes can lead to mechanical irritation.
First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Nitrogen oxides (NO_x)
Sulfur oxides
Chlorine compounds
Metal oxides
Oxides of phosphorus

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.

Etoricoxib Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/02/2020
3.6	04/09/2021	26531-00019	Date of first issue: 10/29/2014

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

- | | | |
|-----------------------------|---|--|
| Technical measures | : | Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres. |
| Local/Total ventilation | : | Use only with adequate ventilation. |
| Advice on safe handling | : | Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment. |
| Conditions for safe storage | : | Keep in properly labeled containers.
Store locked up.
Store in accordance with the particular national regulations. |
| Materials to avoid | : | Do not store with the following product types:
Strong oxidizing agents |

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**Ingredients with workplace control parameters**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	TWA	10 mg/m ³	CA AB OEL
		TWA (Total dust)	10 mg/m ³	CA BC OEL
		TWA (respirable dust fraction)	3 mg/m ³	CA BC OEL
		TWAEV (total dust)	10 mg/m ³	CA QC OEL
		TWA	10 mg/m ³	ACGIH
Etoricoxib	202409-33-4	TWA	400 ug/m ³ (OEB 2)	Internal
Titanium dioxide	13463-67-7	TWA	10 mg/m ³	CA AB OEL
		TWAEV (to-	10 mg/m ³	CA QC OEL

SAFETY DATA SHEET



Etoricoxib Formulation



Version 3.6 Revision Date: 04/09/2021 SDS Number: 26531-00019 Date of last issue: 10/02/2020
 Date of first issue: 10/29/2014

		tal dust)		
		TWA (Total dust)	10 mg/m ³	CA BC OEL
		TWA (respirable dust fraction)	3 mg/m ³	CA BC OEL
		TWA	10 mg/m ³ (Titanium dioxide)	ACGIH

Engineering measures : Ensure adequate ventilation, especially in confined areas. Minimize workplace exposure concentrations. Apply measures to prevent dust explosions. Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment). Dust formation may be relevant in the processing of this product. In addition to substance-specific OELs, general limitations of concentrations of particulates in the air at workplaces have to be considered in workplace risk assessment. Relevant limits include: OSHA PEL for Particulates Not Otherwise Regulated of 15 mg/m³ - total dust, 5 mg/m³ - respirable fraction; and ACGIH TWA for Particles (insoluble or poorly soluble) Not Otherwise Specified of 3 mg/m³ - respirable particles, 10 mg/m³ - inhalable particles.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Choose gloves to protect hands against chemicals depending on the concentration specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

Eye protection : Wear the following personal protective equipment:
Safety goggles

Skin and body protection : Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential. Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

SAFETY DATA SHEET



Etoricoxib Formulation



Version 3.6 Revision Date: 04/09/2021 SDS Number: 26531-00019 Date of last issue: 10/02/2020
Date of first issue: 10/29/2014

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder

Color : colored

Odor : odorless

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapor pressure : No data available

Relative vapor density : No data available

Relative density : No data available

Solubility(ies)
Water solubility : No data available

Partition coefficient: n-octanol/water : No data available

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity
Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

SAFETY DATA SHEET



Etoricoxib Formulation



Version 3.6 Revision Date: 04/09/2021 SDS Number: 26531-00019 Date of last issue: 10/02/2020
Date of first issue: 10/29/2014

Molecular weight : No data available
Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reac- : May form explosive dust-air mixture during processing,
tions handling or other means.
 Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.
 Avoid dust formation.

Incompatible materials : Oxidizing agents
Hazardous decomposition : No hazardous decomposition products are known.
products

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg
Method: Calculation method

Components:

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Etoricoxib:

Acute oral toxicity : LD50 (Rat): 1,499 mg/kg
 LD50 (Mouse): 1,499 mg/kg

Acute toxicity (other routes of : LD50 (Rat): 238 mg/kg
administration) Application Route: Intraperitoneal

 LD50 (Mouse): 599 mg/kg

Etoricoxib Formulation

Version 3.6 Revision Date: 04/09/2021 SDS Number: 26531-00019 Date of last issue: 10/02/2020
Date of first issue: 10/29/2014

Application Route: Intraperitoneal

Titanium dioxide:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity : LC50 (Rat): > 6.82 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Assessment: The substance or mixture has no acute inhalation toxicity

Skin corrosion/irritation

Not classified based on available information.

Components:**Etoricoxib:**

Species : Rabbit
Result : No skin irritation

Titanium dioxide:

Species : Rabbit
Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Etoricoxib:**

Species : Rabbit
Result : Mild eye irritation

Titanium dioxide:

Species : Rabbit
Result : No eye irritation

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:**Etoricoxib:**

Test Type : Local lymph node assay (LLNA)
Routes of exposure : Skin contact
Species : Mouse
Assessment : Did not cause sensitization on laboratory animals.

Etoricoxib Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/02/2020
3.6	04/09/2021	26531-00019	Date of first issue: 10/29/2014

Result : negative

Titanium dioxide:

Test Type : Local lymph node assay (LLNA)
 Routes of exposure : Skin contact
 Species : Mouse
 Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:**Cellulose:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
 Result: negative

Test Type: In vitro mammalian cell gene mutation test
 Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
 Species: Mouse
 Application Route: Ingestion
 Result: negative

Etoricoxib:

Genotoxicity in vitro : Test Type: reverse mutation assay
 Result: negative

Test Type: In vitro mammalian cell gene mutation test
 Test system: human lymphoblastoid cells
 Result: negative

Test Type: Chromosomal aberration
 Test system: Chinese hamster ovary cells
 Result: negative

Test Type: Alkaline elution assay
 Result: negative

Genotoxicity in vivo : Test Type: Chromosomal aberration
 Species: Rat
 Cell type: Bone marrow
 Application Route: Oral
 Result: negative

Test Type: Alkaline elution assay
 Species: Rat
 Application Route: Oral
 Result: negative

Titanium dioxide:

SAFETY DATA SHEET



Etoricoxib Formulation



Version 3.6 Revision Date: 04/09/2021 SDS Number: 26531-00019 Date of last issue: 10/02/2020
Date of first issue: 10/29/2014

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test
Species: Mouse
Result: negative

Carcinogenicity

Suspected of causing cancer if inhaled.

Components:

Cellulose:

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

Etoricoxib:

Species : Rat, male and female
Application Route : oral (gavage)
Exposure time : 2 Years
Result : positive

Species : Mouse, male and female
Application Route : oral (gavage)
Exposure time : 2 Years
Result : negative

Titanium dioxide:

Species : Rat
Application Route : inhalation (dust/mist/fume)
Exposure time : 2 Years
Method : OECD Test Guideline 453
Result : positive
Remarks : The mechanism or mode of action may not be relevant in humans.

Carcinogenicity - Assessment : Limited evidence of carcinogenicity in inhalation studies with animals.

Reproductive toxicity

Suspected of damaging the unborn child.

Components:

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development

SAFETY DATA SHEET



Etoricoxib Formulation



Version 3.6 Revision Date: 04/09/2021 SDS Number: 26531-00019 Date of last issue: 10/02/2020
Date of first issue: 10/29/2014

Species: Rat
Application Route: Ingestion
Result: negative

Etoricoxib:

Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat, female
Application Route: Oral
General Toxicity Parent: NOAEL: 10 mg/kg body weight
Result: positive

Test Type: Fertility/early embryonic development
Species: Rat, male
Application Route: Oral
Result: negative

Effects on fetal development : Species: Rat
Application Route: Oral
Result: positive

Species: Rabbit
Application Route: Oral
Result: positive

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

May cause damage to organs (Kidney, Liver, Gastrointestinal tract) through prolonged or repeated exposure if swallowed.

Components:

Etoricoxib:

Routes of exposure : Ingestion
Target Organs : Kidney, Liver, Gastrointestinal tract
Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Cellulose:

Species : Rat
NOAEL : $\geq 9,000$ mg/kg
Application Route : Ingestion
Exposure time : 90 Days

SAFETY DATA SHEET



Etoricoxib Formulation



Version 3.6 Revision Date: 04/09/2021 SDS Number: 26531-00019 Date of last issue: 10/02/2020
Date of first issue: 10/29/2014

Etoricoxib:

Species : Rat
LOAEL : 30 mg/kg
Application Route : oral (gavage)
Exposure time : 27 Weeks
Target Organs : Gastrointestinal tract, Kidney

Species : Rat
NOAEL : 30 mg/kg
Application Route : oral (gavage)
Exposure time : 53 Weeks
Target Organs : Liver

Species : Dog
NOAEL : 50 mg/kg
Application Route : oral (gavage)
Exposure time : 53 Weeks
Target Organs : Liver

Species : Dog
LOAEL : 200 mg/kg
Application Route : oral (gavage)
Exposure time : 14 Weeks
Target Organs : Gastrointestinal tract, Kidney

Titanium dioxide:

Species : Rat
NOAEL : 24,000 mg/kg
Application Route : Ingestion
Exposure time : 28 Days

Species : Rat
NOAEL : 10 mg/m³
Application Route : inhalation (dust/mist/fume)
Exposure time : 2 y

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Etoricoxib:

Ingestion : Symptoms: upper respiratory tract infection, Headache, hypertension, Diarrhea, urinary tract infection, flu-like symptoms, heartburn, Nausea, bronchitis, Dizziness, asthenia, Rash, Back pain, Cough, Abdominal pain, pharyngitis, Edema

Version	Revision Date:	SDS Number:	Date of last issue: 10/02/2020
3.6	04/09/2021	26531-00019	Date of first issue: 10/29/2014

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Cellulose:**

Toxicity to fish : LC50 (*Oryzias latipes* (Japanese medaka)): > 100 mg/l
 Exposure time: 48 h
 Remarks: Based on data from similar materials

Etoricoxib:

Toxicity to fish : LC50 (*Pimephales promelas* (fathead minnow)): > 30 mg/l
 Exposure time: 96 h
 Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (*Daphnia magna* (Water flea)): > 30 mg/l
 Exposure time: 48 h
 Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (*Pseudokirchneriella subcapitata* (green algae)): > 10 mg/l
 Exposure time: 72 h
 Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity) : NOEC (*Pimephales promelas* (fathead minnow)): 7.93 mg/l
 Exposure time: 32 d
 Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (*Daphnia magna* (Water flea)): 0.75 mg/l
 Exposure time: 21 d
 Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 1,000 mg/l
 Exposure time: 3 h
 Test Type: Respiration inhibition
 Method: OECD Test Guideline 209

NOEC: 1,000 mg/l
 Exposure time: 3 h
 Test Type: Respiration inhibition
 Method: OECD Test Guideline 209

Titanium dioxide:

Toxicity to fish : LC50 (*Oncorhynchus mykiss* (rainbow trout)): > 100 mg/l
 Exposure time: 96 h
 Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (*Daphnia magna* (Water flea)): > 100 mg/l
 Exposure time: 48 h

Toxicity to algae/aquatic plants : EC50 (*Skeletonema costatum* (marine diatom)): > 10,000 mg/l
 Exposure time: 72 h

SAFETY DATA SHEET



Etoricoxib Formulation



Version 3.6 Revision Date: 04/09/2021 SDS Number: 26531-00019 Date of last issue: 10/02/2020
Date of first issue: 10/29/2014

Toxicity to microorganisms : EC50: > 1,000 mg/l
Exposure time: 3 h
Method: OECD Test Guideline 209

Persistence and degradability

Components:

Cellulose:

Biodegradability : Result: Readily biodegradable.

Etoricoxib:

Biodegradability : Result: not rapidly degradable
Biodegradation: 0.2 %
Exposure time: 28 d

Bioaccumulative potential

Components:

Etoricoxib:

Partition coefficient: n-octanol/water : log Pow: 2.3

Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Etoricoxib)
Class : 9
Packing group : III
Labels : 9

IATA-DGR

UN/ID No. : UN 3077

SAFETY DATA SHEET



Etoricoxib Formulation



Version 3.6 Revision Date: 04/09/2021 SDS Number: 26531-00019 Date of last issue: 10/02/2020
Date of first issue: 10/29/2014

Proper shipping name : Environmentally hazardous substance, solid, n.o.s.
(Etoricoxib)
Class : 9
Packing group : III
Labels : Miscellaneous
Packing instruction (cargo aircraft) : 956
Packing instruction (passenger aircraft) : 956
Environmentally hazardous : yes

IMDG-Code

UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,
N.O.S.
(Etoricoxib)
Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

TDG

UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,
N.O.S.
(Etoricoxib)
Class : 9
Packing group : III
Labels : 9
ERG Code : 171
Marine pollutant : yes(Etoricoxib)

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

The ingredients of this product are reported in the following inventories:

AICS : not determined
DSL : not determined
IECSC : not determined

SAFETY DATA SHEET



Etoricoxib Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 10/02/2020
3.6	04/09/2021	26531-00019	Date of first issue: 10/29/2014

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8